Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LIOTHYRONINE (SODIUM)

All products: not a benefit

Other products in the same Health Canada class (H03AA) — coverage varies; not interchangeable

  • Levothyroxine (Synthroid): general benefit, Not a benefit

ZDS-Liothyronine · DIN 02561301 · 25mcg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
ZDS-Liothyronine · DIN 02561301 Manufacturer: Zydus; listing date 2026-01-30 Health Canada: Marketed since 2026-01-15 · brand ZDS-LIOTHYRONINE · ATC H03AA02 LIOTHYRONINE SODIUM · form Tablet · route Oral · ingredients LIOTHYRONINE (LIOTHYRONINE SODIUM) 25 MCG · company Zydus lifesciences limited · schedule Prescription
Check this DIN again · Health Canada product record

ZDS-Liothyronine: Formulary list price $1.2595/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2595 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106428 · Verify on the e-Formulary ↗ (DIN 02561301)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02561301). DIN 02561301: ZDS-Liothyronine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 683600006; group id 806; item number 1982; lccId None; manufacturer id ZDS Source form: Tab; strength: 25mcg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $1.2595; ministry $1.2595 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02561301 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106428
Interchangeable products
Auro-Liothyronine · DIN 02550008 · $1.2595 Cytomel · DIN 01919466 · not recorded Teva-Liothyronine · DIN 02494345 · $1.2595
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02561301
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:36 Thyroids) and how they are covered

Matched class: 68:36 Thyroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PROPYLTHIOURACIL Some products covered without a code (check the product listing): LEVOTHYROXINE (SODIUM) 68:36 Thyroids

LEVOTHYROXINE (SODIUM)

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (26) · strengths: 0.137mg, 0.025mg, 0.05mg, 0.075mg, 0.088mg, 0.1mg, 0.112mg, 0.125mg, 0.15mg, 0.175mg, 0.2mg, 0.3mg · Tab

PROPYLTHIOURACIL

· 2 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:36
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USES Cytomel® is indicated in conditions of inadequate endogenous thyroid production. These: include: a. HYPOTHYROIDISM: As replacement or supplemental therapy in patients with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis b. SIMPLE (non-toxic) GOITER: Cytomel® may be tried therapeutically in an attempt to reduce the size of such a goiter, the rationale being that suppression of pituitary thyroid stimulating hormone (TSH) removes at least one of the growth-promoting factors. Cytomel® may be used in the T3 suppression test to differentiate suspected hyperthyroidism from euthyroidism. (See special instructions under ADMINISTRATION AND DOSAGE), Cytomel® can be used in patients allergic to dessicated thyroid or thyroid extract derived from pork or beef. Use in Pregnancy: See WARNINGS and PRECAUTIONS Use in Nursing Mothers: See WARNINGS and PRECAUTIONS Pediatric Use: See WARNINGS and PRECAUTIONS and DOSAGE and ADMINISTRATION Geriatic Use: See WARNINGS and PRECAUTIONS and DOSAGE and ADMINISTRATION https://pdf.hres.ca/dpd_pm/00040301.PDF PM date: July 25, 2017 Source product: CYTOMEL; DIN 01919458; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For ZDS-Liothyronine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026